nilvadipine has been researched along with Diabetes Mellitus, Type 2 in 5 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 7.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| "To evaluate the effects of cilnidipine (CNP), L- and N-type calcium channel blocker and nilvadipine (NVP) on 24-h urinary epinephrine (U-EP), norepinephrine (U-NE), dopamine (U-DA) and C-peptide (U-CPR) in patients associated with hypertension and non-insulin-dependent diabetes mellitus (HT-NIDDM), a randomized crossover study was performed with 35 HT-NIDDM patients." | 5.09 | Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. ( Hattori, Y; Irie, M; Takeda, S; Ueshiba, H, 1999) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 3.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moriyama, T | 1 |
| Oka, K | 1 |
| Ueda, H | 1 |
| Imai, E | 1 |
| Dohmen, W | 1 |
| Sone, H | 1 |
| Okuda, Y | 1 |
| Mizutani, M | 1 |
| Kawakami, Y | 1 |
| Bannai, C | 1 |
| Yamashita, K | 2 |
| Takeda, S | 1 |
| Ueshiba, H | 1 |
| Hattori, Y | 1 |
| Irie, M | 1 |
| Kawai, K | 1 |
| Suzuki, S | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
4 trials available for nilvadipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Investigation on the blood pressure-independent nephroprotective effect of nilvadipine in type 2 diabetics].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; | 2008 |
The effect of nilvadipine on bloodflow in the dorsal pedis artery in type 2 diabetic patients--a study using duplex Doppler ultrasonography.
Topics: Arteries; Blood Flow Velocity; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Foot; Hu | 1995 |
Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus.
Topics: Aged; C-Peptide; Calcium Channel Blockers; Catecholamines; Chromatography, High Pressure Liquid; Cro | 1999 |
Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Blood Glucose; Blo | 1992 |
1 other study available for nilvadipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2004 |